Core Viewpoint - Eli Lilly's new drug Inluriyo has been approved by the FDA for adult patients with previously treated advanced breast cancer, showing a 38% reduction in the risk of cancer progression or death compared to standard treatments [1][2]. Group 1: Drug Approval and Mechanism - The FDA approval of Inluriyo is based on data from a late-stage clinical trial [1]. - Inluriyo targets overactive estrogen receptors caused by ESR1 gene mutations, blocking their activity and promoting their degradation to slow cancer spread [1]. Group 2: Clinical Trial Results - Patients treated with Inluriyo experienced an average of 5.5 months without disease progression, compared to 3.8 months for those receiving other treatments [2]. - The recommended dosage for Inluriyo is 400 mg, taken once daily on an empty stomach [2]. Group 3: Market and Future Research - Inluriyo is expected to be available in the U.S. within weeks, priced at $22,500 for a 28-day course [1]. - Eli Lilly is conducting further trials to explore the combination of Inluriyo with another drug, abemaciclib, and its potential as an adjuvant therapy for early breast cancer [2].